Jonathan S Wall

Jonathan Wall is a tenured Distinguished Professor and Asst. Dean for Research at the University of Tennessee Graduate School of Medicine. He has over 100 publications and 29 issued US and international patents. He graduated from the University of Essex (Colchester, UK) with a PhD in Biological Chemistry and Biophysics. He joined the Human Immunology & Cancer Program at the University of Tennessee Medical Center, Knoxville as a post-doctoral fellow, where he worked on elucidating biochemical and biophysical aspects of immunoglobulin light chain amyloidosis. He helped establish a Preclinical Imaging Laboratory to study the biodistribution of amyloid-reactive antibodies, which resulted in a “first-in-human” PET/CT imaging trial of the 124I-11-1F4 therapeutic antibody (now CAEL-101) in patients with light chain-associated (AL) amyloidosis. He now serves as Director of the NIH-funded Amyloidosis and Cancer Theranostics Program at University of Tennessee Graduate School of Medicine, Knoxville where the focus remains on the development and translation of biological agents for imaging and treatment of systemic amyloid diseases. In 2018, this group initiated a first-in human Phase 1 PET/CT imaging trial of a novel pan-amyloid diagnostic peptide (with support from the NHLBI/SMARTT program). In 2011, Dr. Wall, with colleagues from the ACTP founded Solex, LLC to develop amyloid reactive peptides as diagnostic agents. In 2020, Solex became Attralus Inc., which secured $25M in series A funding, followed by $116M in Series B investment in September 2021. Attralus, Inc., is now a clinical stage biopharmaceutical company working, in collaboration with the Amyloidosis and Cancer Thernaostics Program, to develop transformative medicines to improve the lives of patients with systemic amyloidosis using pan-amyloid removal technologies.